Trientine and Carboplatin in Advanced Malignancies

Phase 1 Completed 56 enrolled M.D. Anderson Cancer Center

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Timeline

Start: 2010-07
Primary completion: 2014-08
Completion: 2014-08

Publications

Fu S, Naing A, Fu C, Kuo MT, Kurzrock R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012 Jun;11(6):1221-5. doi: 10.1158/1535-7163.MCT-11-0864. Epub 2012 Apr 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	4 unknown	Intravenous
Subject	trientine	Unknown	750 mg	Oral

Trientine and Carboplatin in Advanced Malignancies

Summary

Timeline

Publications

Drugs

Indications